publication venue for
- AI informed virtual immunocyte profiling from H&E images predicts immunotherapy response (VIPER) in head and neck squamous cell carcinoma 2025
- NRG-HN014 (C-PRE): A randomized phase III study of neoadjuvant immunotherapy with response-adapted treatment versus standard-of-care treatment for patients with resectable stage III-IV (M0) cutaneous squamous cell carcinoma (cSCC) 2025
- Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer 2016
- Immune biomarkers of anti-EGFR monoclonal antibody therapy 2015